Evidence map›Paper›PMID 41910762›Full record

ReviewDie Ophthalmologie2026

[Endophthalmitis with keratitis-how to manage severe cases? : A narrative review].

Sundaram Natarajan, Mauricio Bayram-Suverza, Itzel Aguilar-Valdez, Mary Lady González-Suriel

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sundaram NatarajanClinical Services, Aditya Jyot Eye Hospital, Mumbai, Indien.
Mauricio Bayram-SuverzaRetina Department, Fundación Hospital Nuestra Señora de La Luz, Mexico City, Mexiko. mauricio.bayram@gmail.com.ORCID http://orcid.org/0000-0002-0995-4252
Itzel Aguilar-ValdezCornea Department, Asociación para Evitar la Ceguera en México, Mexico City, Mexiko.ORCID http://orcid.org/0000-0003-0680-6403
Mary Lady González-SurielComprehensive Ophthalmology Department, Asociación para Evitar la Ceguera en México, Mexico City, Mexiko.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endophthalmitis secondary to microbial keratitis (MK) is a rare but devastating ophthalmic emergency characterized by diagnostic and therapeutic challenges due to poor corneal clarity. Although it accounts for less than 10% of cases of exogenous endophthalmitis, it often results in poor visual outcomes or enucleation. The most common causative organisms include Staphylococcus spp., Pseudomonas spp., and Fusarium spp., with rising concerns about antimicrobial resistance. Several risk factors have been identified, including the use of topical corticosteroids, systemic immunosuppression, and fungal infections, particularly those caused by Fusarium. Early and aggressive management is essential, combining intravitreal antimicrobials with surgery to reduce the microbiological load. When corneal opacity limits visualization, a combined approach involving temporary keratoprosthesis, penetrating keratoplasty, and pars plana vitrectomy may offer a chance to salvage the eye. This narrative review synthesizes the current understanding of MK-associated endophthalmitis and presents updated management strategies to optimize visual and anatomical outcomes in these severe cases.

Indexed as

EndophthalmitisEye Infections, BacterialKeratitisCombined Modality TherapyEye EnucleationEye Infections, FungalHumansKeratoplasty, PenetratingRisk FactorsVitrectomyEye enucleationEye eviscerationIntravitreal InjectionsKeratoplasty, penetratingVitrectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.